Search

Displaying results 5111 - 5120 of 10000 in total
  1. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  2. Drug

    OSI-027

    go.drugbank.com/drugs/DB12387
    Investigational

    OSI-027 has been used in trials studying the treatment of Any Solid Tumor or Lymphoma.

  3. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  4. Drug

    Flumequine

    go.drugbank.com/drugs/DB08972
    ApprovedWithdrawn

    Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

  5. Drug

    Leriglitazone

    go.drugbank.com/drugs/DB15021
    Investigational

    Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).

  6. Drug

    Vofatamab

    go.drugbank.com/drugs/DB14781
    Investigational

    Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).

  7. Drug

    Enarodustat

    go.drugbank.com/drugs/DB14985
    Investigational

    Enarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).

  8. Drug

    Inupadenant

    go.drugbank.com/drugs/DB19129
    Investigational

    Inupadenant is under investigation in clinical trial NCT05060432 (Study of EOS-448 With Standard of Care And/or Investigational Therapies in Participants With Advanced Solid Tumors).

  9. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance

  10. Drug

    Sulesomab

    go.drugbank.com/drugs/DB13976
    Approved

    Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.